Single-center clinical study for embolization with irinotecan loaded microspheres in the treatment of hepatic metastasis from neuroendocrine carcinoma

Clinical study for embolization with irinotecan loaded microspheres in the treatment of hepatic metastasis from neuroendocrine carcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021388

Enrollment

Unknown

Registered

2019-02-18

Start date

2019-03-31

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroendocrine carcinoma

Interventions

Case series:DEB-IRI

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The study was to select patients with liver metastasis of neuroendocrine tumors confirmed by pathology, including those with liver metastasis of highly proliferative neuroendocrine tumors (Ki-67 > 15% in G3 or G2) or liver metastasis of neuroendocrine tumors (G1 or G2), who were treated by interventional embolization and confirmed to be in accordance with the indications of interventional therapy by multidisciplinary consultation.

Exclusion criteria

Exclusion criteria: Unsuitable for interventional therapy after evaluation

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactPeng Liu

Beijing Cancer Hospital

dr.liu@163.com+86 18500644600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026